Immunocellular Therapeutics, Ltd. (NYSE: IMUC) reported Q1 EPS of ($0.05), in-line with the analyst estimate of ($0.05). The net loss for the most recent quarter reflects a charge of $416,000 related to the revaluation of the Company's warrant derivatives.

For earnings history and earnings-related data on Immunocellular Therapeutics, Ltd. (IMUC) click here.